甲亢患者血清糖基化终产物的检测及临床意义  

Significance of serum advanced glycosylation end products in patients with Graves disease

作　　者：金晖[1] 孙子林[1] 张林[1] 鞠昌萍[1] 

机构地区：[1]东南大学附属中大医院内分泌科,江苏南京210009

出　　处：《华夏医学》2005年第1期15-16,共2页Acta Medicinae Sinica

摘　　要：目的 :观察 Graves病 (GD)甲亢患者血清中 AGEs的变化 ,并探讨其临床意义。方法 :使用荧光光谱测定法分别检测 GD患者、GD伴血糖调节受损者血清中 AGEs水平 ,并与健康者比较。结果 :5 0例 GD患者 AGEs值为 (13.81±1.2 8) μg/ ml,明显高于健康人组 (7.6 9± 0 .5 6 ) μg/ ml(P<0 .0 1) ,甲亢伴血糖调节受损者 ,AGEs值比单纯甲亢者明显升高 ,具有极显著性差异 (P<0 .0 1)。结论 :GD与糖代谢紊乱之间关系密切 ,患者体内非酶促糖基化反应明显增强。Objective: To detect the serum advanced glycosylation end products in patients with Graves disease. Me- thods: Serum of 50 patients with GD,GD with impaired of glucose tolerence was detected for analyzing F-AGE by fluorescence spectroscope. Results:The serum F-AGE of patients with GD and GD with impaired of glucose tolerence were significantly higher than those of control,especially the latter. Conclusion:Increased level of AGEs is seen in GD.

关 键 词：GRAVES病 糖基化终产物 血糖 

分 类 号：R581.1[医药卫生—内分泌] R589.1[医药卫生—内科学]